Therapeutic targeting of CD146/MCAM reduces bone metastasis in prostate cancer

17Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Prostate Cancer is the most common cancer and the second leading cause of cancer-related death in males. When prostate cancer acquires castration resistance, incurable metastases, primarily in the bone, occur. The aim of this study is to test the applicability of targeting melanoma cell adhesion molecule (MCAM; CD146) with a mAb for the treatment of lytic prostate cancer bone metastasis. We evaluated the effect of targeting MCAM using in vivo preclinical bone metastasis models and an in vitro bone niche coculture system. We utilized FACS, cell proliferation assays, and gene expression profiling to study the phenotype and function of MCAM knockdown in vitro and in vivo. To demonstrate the impact of MCAM targeting and therapeutic applicability, we employed an anti-MCAM mAb in vivo. MCAM is elevated in prostate cancer metastases resistant to androgen ablation. Treatment with DHT showed MCAM upregulation upon castration. We investigated the function of MCAM in a direct coculture model of human prostate cancer cells with human osteoblasts and found that there is a reduced influence of human osteoblasts on human prostate cancer cells in which MCAM has been knocked down. Furthermore, we observed a strongly reduced formation of osteolytic lesions upon bone inoculation of MCAM-depleted human prostate cancer cells in animal model of prostate cancer bone metastasis. This phenotype is supported by RNA sequencing (RNA-seq) analysis. Importantly, in vivo administration of an anti-MCAM human mAb reduced the tumor growth and lytic lesions. These results highlight the functional role for MCAM in the development of lytic bone metastasis and suggest that MCAM is a potential therapeutic target in prostate cancer bone metastasis. Implications: This study highlights the functional application of an anti-MCAM mAb to target prostate cancer bone metastasis.

References Powered by Scopus

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

34907Citations
N/AReaders
Get full text

Cytoscape: A software Environment for integrated models of biomolecular interaction networks

33931Citations
N/AReaders
Get full text

STAR: Ultrafast universal RNA-seq aligner

28552Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cell adhesion molecules in plasticity and metastasis

34Citations
N/AReaders
Get full text

Transmembrane MUC18 Targeted Polydopamine Nanoparticles and a Mild Photothermal Effect Synergistically Disrupt Actin Cytoskeleton and Migration of Cancer Cells

26Citations
N/AReaders
Get full text

Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification

22Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zoni, E., Astrologo, L., Ng, C. K. Y., Piscuoglio, S., Melsen, J., Grosjean, J., … Thalmann, G. N. (2019). Therapeutic targeting of CD146/MCAM reduces bone metastasis in prostate cancer. Molecular Cancer Research, 17(5), 1049–1062. https://doi.org/10.1158/1541-7786.MCR-18-1220

Readers over time

‘19‘20‘21‘22‘23‘2405101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

57%

Researcher 6

29%

Professor / Associate Prof. 3

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

35%

Biochemistry, Genetics and Molecular Bi... 6

35%

Agricultural and Biological Sciences 3

18%

Immunology and Microbiology 2

12%

Save time finding and organizing research with Mendeley

Sign up for free
0